Citations

Clear

626 citation(s) found for "Mehta, SH".

Cardiac sympathetic denervation and synucleinopathy in Alzheimer’s disease with brain Lewy body disease
Callan, Michael, Cutler, Brett, Glass, Michael J. , Walker, Jessica E. , Intorcia, Anthony J., Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Sue, Lucia I., Vargas, Daisy, Beach, Thomas G. , Driver-Dunckley, Erika, Serrano, Geidy E. , Shprecher, David , Zhang, Nan , Adler, Charles H.

Mayo Clinic

Brain Communications | January 28, 2020 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaa004 | PMID 32064463 Get It

Abstract Comorbid Lewy body pathology is very common in Alzheimer’s disease and may confound clinical trial design, yet there is no in vivo test to identify patients with this. Tissue (and/or radioligand imaging) studies have shown cardiac sympathetic denervation in Parkinson’s disease and dementia with Lewy bodies, but this has not been explored in Alzheimer’s subjects with Lewy bodies not meeting dementia with Lewy bodies clinicopathological criteria. To determine if Alzheimer’s disease with Lewy bodies subjects show sympathetic cardiac denervation, we analysed epicardial and myocardial tissue from autopsy-confirmed cases using tyrosine hydroxylase and neurofilament immunostaining. Comparison of tyrosine hydroxylase fibre density in 19 subjects with Alzheimer’s disease/dementia with Lewy bodies, 20 Alzheimer’s disease with Lewy bodies, 12 Alzheimer’s disease subjects without Lewy body disease, 19 Parkinson’s disease, 30 incidental Lewy body disease and 22 cognitively normal without Alzheimer’s disease or Lewy body disease indicated a significant group difference (P < 0.01; Kruskal–Wallis analysis of variance) and subsequent pair-wise Mann–Whitney U tests showed that Parkinson’s disease (P < 0.05) and Alzheimer’s disease/dementia with Lewy bodies (P < 0.01) subjects, but not Alzheimer’s disease with Lewy bodies subjects, had significantly reduced tyrosine hydroxylase fibre density as compared with cognitively normal. Both Parkinson’s disease and Alzheimer’s disease/dementia with Lewy bodies subjects also showed significant epicardial losses of neurofilament protein-immunoreactive nerve fibre densities within the fibre bundles as compared with cognitively normal subjects (P < 0.01) and both groups showed high pathologic alpha-synuclein densities (P < 0.0001). Cardiac alpha-synuclein densities correlated significantly with brain alpha-synuclein (P < 0.001), while cardiac tyrosine hydroxylase and neurofilament immunoreactive nerve fibre densities were negatively correlated with the densities of both brain and cardiac alpha-synuclein, as well as Unified Parkinson’s Disease Rating Scale scores (P < 0.05). The clear separation of Alzheimer’s disease/dementia with Lewy bodies subjects from Alzheimer’s disease and cognitively normal, based on cardiac tyrosine hydroxylase fibre density, is the first report of a statistically significant difference between these groups. Our data do not show significant sympathetic cardiac denervation in Alzheimer’s disease with Lewy bodies, but strongly confirm that cardiac nuclear imaging with a noradrenergic radioligand is worthy of further study as a potential means to separate Alzheimer’s disease from Alzheimer’s disease/dementia with Lewy bodies during life.
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head
Abrams, Ross A. , Winter, Kathryn, Safran, Howard , Regine, William F., Berger, Adam C. , Gillin, Michael T. , Lowy, Andrew M. , DiPetrillo, Thomas A., Corn, Benjamin W. , Seaward, Samantha A. , Haddock, Michael G. , Song, Suisui, Jiang, Yixing , Fisher, Barbara J., Mehta, Sharmila, Willett, Christopher G. , Crane, Christopher H. , Seaward, Samantha A , Goodman, Karyn A. , Philip, Philip A. , Wu, Abraham J , Katz, Alan W.

Mayo Clinic

American Journal of Clinical Oncology | January 27, 2020 | Volume: 43 | Issue: 3 | Pages: 173-179

10.1097/coc.0000000000000633 | PMID 31985516 Get It

Purpose: NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. Methods: Eligibility—within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180. Gemcitabine arm—6 cycles of gemcitabine. Gemcitabine+erlotinib arm—gemcitabine and erlotinib 100 mg/d. Two hundred deaths provided 90% power (1-sided α=0.15) to detect the hypothesized OS signal (hazard ratio=0.72) in favor of the arm 2. Results: From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2. Median age was 63 (39 to 86) years. CA19-9 ≤90 in 93%. Arm 1: 32 patients (20%) grade 4 and 2 (1%) grade 5 adverse events; arm 2, 27 (17%) grade 4 and 3 (2%) grade 5. GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, ( P =0.22). The median follow-up (surviving patients) was 42.5 months (min-max: <1 to 75). With 203 deaths, the median and 3-year OS (95% confidence interval) are 29.9 months (21.7, 33.4) and 39% (30, 45) for arm 1 and 28.1 months (20.7, 30.9) and 39% (31, 47) for arm 2 (log-rank P =0.62). Hazard ratio (95% confidence interval) comparing OS of arm 2 to arm 1 is 1.04 (0.79, 1.38). Conclusions: The addition of adjuvant erlotinib to gemcitabine did not provide a signal for increased OS in this trial.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients
Lee, Eudocia Q. , Weller, Michael , Sul, Joohee, Bagley, Stephen , Sahebjam, Solmaz , Bent, Martin J. van den , Ahluwalia, Manmeet S. , Campian, Jian , Holdhoff, Matthias , Lesser, Glenn J. , Lieberman, Frank S. , Peñas-Prado, Marta , Schreck, Karisa C. , Vogelbaum, Michael A. , Walbert, Tobias , Chang, Susan M. , Reardon, David A. , Wen, Patrick Y. , Weller, Michael , van den Bent, Martin J , Ahluwalia, Manmeet S , Galanis, Evanthia , Gilbert, Mark R. , Mehta, Minesh P. , Strowd, Roy E. , Chang, Susan Marina , Nabors, Burt , Grossman, Stuart A. , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | January 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noaa015 | PMID 31974566 Get It

AbstractBuilding on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival
Lee, David D. , Mehta, Neil , Gorgen, Andre , Musto, Kaitlyn R., Hajda, Hana, Yao, Francis Y. , Hodge, David O. , Carter, Rickey E. , Harnois, Denise M. , Lee, David D , Carter, Rickey E , Sapisochín, Gonzalo

Mayo Clinic

Transplantation | January 16, 2020 | Volume: 104 | Issue: 10 | Pages: 2105-2112

10.1097/tp.0000000000003117 | PMID 31972705 Get It

Background. Currently, no surveillance guidelines for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) exist. In this retrospective, multicenter study, we have investigated the role of surveillance imaging on postrecurrence outcomes. Methods. Patients with recurrent HCC after LT from 2002 to 2016 were reviewed from 3 transplant centers (University of California San Francisco, Mayo Clinic Florida, and University of Toronto). For this study, we proposed the term cumulative exposure to surveillance (CETS) as a way to define the cumulative sum of all the protected intervals that each surveillance test provides. In our analysis, CETS has been treated as a continuous variable in months. Results. Two hundred twenty-three patients from 3 centers had recurrent HCC post-LT. The median follow-up was 31.3 months, and median time to recurrence was 13.3 months. Increasing CETS was associated with improved postrecurrence survival (hazard ratio, 0.94; P < 0.01) as was treatment of recurrence with resection or ablation (hazard ratio, 0.31; P < 0.001). An receiver operating characteristic curve (area under the curve, 0.64) for CETS covariate showed that 252 days of coverage (or 3 surveillance scans) within the first 24 months provided the highest probability for aggressive postrecurrence treatment. Conclusions. In this review of 223 patients with post-LT HCC recurrence, we found that increasing CETS does lead to improved postrecurrence survival as well as a higher probability for aggressive recurrence treatment. We found that 252 days of monitoring (ie, 3 surveillance scans) in the first 24 months was associated with the ability to offer potentially curative treatment.
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, Kristin A. , Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Diver, W. Ryan , Hennis, Anselm , Nemesure, Barbara , Klein, Eric A. , Rybicki, Benjamin A. , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Stephens, Owen , Zangari, Maurizio , Hu, Jennifer J. , Nyante, Sarah J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Tomasson, Michael H. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Chiu, Brian C.‐H. , Ziv, Elad , Vij, Ravi , Bernal‐Mizrachi, Leon , Morgan, Gareth J. , Zonder, Jeffrey A. , Huff, Carol Ann , Orlowski, Robert Z. , Conti, David V. , Haiman, Christopher A. , Orlowski, Robert Z. , John, Esther M , Klein, Eric A , Nyante, Sarah , Morgan, Gareth J , Ziv, Elad , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Bernstein, Leslie , Rhee, Frits van , Olshan, Andrew F. , Zheng, Wei , Ziegler, Regina G. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Stram, Daniel O. , Lonial, Sagar , Cozen, Wendy

Mayo Clinic

Blood Advances | January 14, 2020 | Volume: 4 | Issue: 1 | Pages: 181-190

10.1182/bloodadvances.2019000491 | PMID 31935283 Get It

Abstract Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of EA. Little is known about genetic risk factors for MM in individuals of AA. We performed a meta-analysis of 2 GWASs of MM in 1813 cases and 8871 controls and conducted an admixture mapping scan to identify risk alleles. We fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. In GWAS meta-analysis, we identified 2 suggestive novel loci located at 9p24.3 and 9p13.1 at P &lt; 1 × 10−6; however, no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. Of the 23 known EA risk variants, 20 showed directional consistency, and 9 replicated at P &lt; .05 in AA individuals. In 8 regions, we identified markers that better capture MM risk in persons with AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95% confidence interval, 1.56-2.11) increased MM risk compared with those with average risk (25%-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P = 5.1 × 10−12). Our study shows that common genetic variation contributes to MM risk in individuals with AA.
Unconventional Diagnosis Based on Somatic Findings through Germ Line Whole-Exome Sequencing
Lopes, Jaime L. , Rasmussen, Kristen , Mehta, Nikita , Boczek, Nicole J. , Hasadsri, Linda , Rasmussen, Kristen J , Lopes, Jaime

Mayo Clinic

Clinical Chemistry | January 6, 2020 | Volume: 66 | Issue: 1 | Pages: 48-51

10.1093/clinchem.2019.304451 | PMID 32609848 Get It

Defining the human kidney N‐glycome in normal and cancer tissues using MALDI imaging mass spectrometry
Drake, Richard R. , McDowell, Colin T. , West, Connor A., David, F., Powers, Thomas W. , Nowling, Tamara K. , Bruner, Evelyn, Mehta, Anand S. , Angel, Peggi M. , Copland, John A. , Marlow, Laura A. , Tun, Han W. , Angel, Peggi , Drake, Richard , David, Fred

Mayo Clinic

Journal of Mass Spectrometry | December 20, 2019 | Volume: 55 | Issue: 4 | Pages: No page available

10.1002/jms.4490 | PMID 31860772 Get It

AbstractClear‐cell renal cell carcinoma (ccRCC) presents challenges to clinical management because of late‐stage detection, treatment resistance, and frequent disease recurrence. Metabolically, ccRCC has a well‐described Warburg effect utilization of glucose, but how this affects complex carbohydrate synthesis and alterations to protein and cell surface glycosylation is poorly defined. Using an imaging mass spectrometry approach, N‐glycosylation patterns and compositional differences were assessed between tumor and nontumor regions of formalin‐fixed clinical ccRCC specimens and tissue microarrays. Regions of normal kidney tissue samples were also evaluated for N‐linked glycan‐based distinctions between cortex, medullar, glomeruli, and proximal tubule features. Most notable was the proximal tubule localized detection of abundant multiantennary N‐glycans with bisecting N‐acetylglucosamine and multziple fucose residues. These glycans are absent in ccRCC tissues, while multiple tumor‐specific N‐glycans were detected with tri‐ and tetra‐antennary structures and varying levels of fucosylation and sialylation. A polycystic kidney disease tissue was also characterized for N‐glycan composition, with specific nonfucosylated glycans detected in the cyst fluid regions. Complementary to the imaging mass spectrometry analyses was an assessment of transcriptomic gene array data focused on the fucosyltransferase gene family and other glycosyltransferase genes. The transcript levels of the FUT3 and FUT6 genes responsible for the enzymes that add fucose to N‐glycan antennae were significantly decreased in all ccRCC tissues relative to matching nontumor tissues. These striking differences in glycosylation associated with ccRCC could lead to new mechanistic insight into the glycobiology underpinning kidney malignancies and suggest the potential for new therapeutic interventions and diagnostic markers.
Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy
Bian, Xiaohui , Griffin, Tomás P. , Zhu, Xiangyang , Islam, Md Nahidul , Conley, Sabena M., Eirin, Alfonso , O’Shea, Paula , McCoy, Rozalina G. , Mehta, Ramila A. , Woollard, John R. , Kirkland, James L. , Textor, Stephen C., Griffin, Matthew D. , Lerman, Lilach O. , Palmer, Allyson K. , McCoy, Rozalina Grubina , Woollard, John R , Griffin, Matthew D , Lerman, Lilach O , Hickson, LaTonya J , Eirin, Alfonso , O'Shea, Paula M , Tang, Hui Jun , Herrmann, Sandra M. , Rule, Andrew D. , Tchkonia, Tamar , Hickson, LaTonya J.

Mayo Clinic

BMJ Open Diabetes Research & Care | December 16, 2019 | Volume: 7 | Issue: 1 | Pages: e000720

10.1136/bmjdrc-2019-000720 | PMID 31908790 Get It

Objective Activin A, an inflammatory mediator implicated in cellular senescence-induced adipose tissue dysfunction and profibrotic kidney injury, may become a new target for the treatment of diabetic kidney disease (DKD) and chronic kidney diseases. We tested the hypothesis that human DKD-related injury leads to upregulation of activin A in blood and urine and in a human kidney cell model. We further hypothesized that circulating activin A parallels kidney injury markers in DKD. Research design and methods In two adult diabetes cohorts and controls (Minnesota, USA; Galway, Ireland), the relationships between plasma (or urine) activin A, estimated glomerular filtration rate (eGFR) and DKD injury biomarkers were tested with logistic regression and correlation coefficients. Activin A, inflammatory, epithelial-mesenchymal-transition (EMT) and senescence markers were assayed in human kidney (HK-2) cells incubated in high glucose plus transforming growth factor-β1 or albumin. Results Plasma activin A levels were elevated in diabetes (n=206) compared with controls (n=76; 418.1 vs 259.3 pg/mL; p<0.001) and correlated inversely with eGFR (r s =−0.61; p<0.001; diabetes). After eGFR adjustment, only albuminuria (OR 1.56, 95% CI 1.16 to 2.09) and tumor necrosis factor receptor-1 (OR 6.40, 95% CI 1.08 to 38.00) associated with the highest activin tertile. Albuminuria also related to urinary activin (r s =0.65; p<0.001). Following in vitro HK-2 injury, activin, inflammatory, EMT genes and supernatant activin levels were increased. Conclusions Circulating activin A is increased in human DKD and correlates with reduced kidney function and kidney injury markers. DKD-injured human renal tubule cells develop a profibrotic and inflammatory phenotype with activin A upregulation. These findings underscore the role of inflammation and provide a basis for further exploration of activin A as a diagnostic marker and therapeutic target in DKD.
Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change
Brondfield, Max N. , Hirose, Ryutaro , Yao, Francis Y. , Mehta, Neil , Mehta, Neil , Dodge, Jennifer L. , Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | December 13, 2019 | Volume: 26 | Issue: 5 | Pages: 662-672

10.1002/lt.25701 | PMID 31833634 Get It

For patients with hepatocellular carcinoma (HCC) listed for liver transplantation (LT), United Network for Organ Sharing (UNOS) enacted policy changes in 2015 to improve equity between HCC and non‐HCC patients. We evaluated the impact of these changes on regional disparities in wait‐list dropout and LT. We included patients in the UNOS database listed with Model for End‐Stage Liver Disease HCC exceptions in long‐wait regions (LWRs), mid‐wait regions (MWRs), and short‐wait regions (SWRs) before these policy changes (era 1, January 1 to December 31, 2013) and after (era 2, October 7, 2015, to October 7, 2016). Cumulative incidence of wait‐list dropout and LT were evaluated using competing risk regression. Median time to LT increased by 3.6 months (3.1 to 6.7 months) in SWRs and 1.3 months (6.9 to 8.2 months) in MWRs (P < 0.001), with a slight decrease in LWRs (13.4 to 12.9 months; P = 0.02). The 2‐year cumulative incidence of dropout increased from 9.7% to 14.8% in SWRs (P = 0.03) and from 18.9% to 22.6% in MWRs (P = 0.18) but decreased in LWRs from 26.7% to 24.8% (P = 0.31). Factors predicting wait‐list dropout included listing in era 2 (hazard ratio [HR], 1.17), in LWRs (HR, 2.56), and in MWRs (HR, 1.91). Regional differences in wait‐list outcomes decreased with policy changes, but HCC patients in SWRs remain advantaged. Recent policy change may narrow these disparities.
Competency‐Based Assessment Tool for Pediatric Tracheotomy: International Modified Delphi Consensus
Propst, Evan J. , Wolter, Nikolaus E. , Ishman, Stacey L. , Balakrishnan, Karthik , Deonarain, Ashley R. , Mehta, Deepak, Zalzal, George H., Pransky, Seth M. , Roy, Soham , Myer, Charles M. , Torre, Michele , Johnson, Romaine F. , Lüdemann, Jeffrey P. , Derkay, Craig S. , Hong, Paul , Molter, David, Prager, Jeremy D. , Nguyen, Lily H. P. , Rutter, Michael J. , Zur, Karen B. , Sidell, Douglas R. , Johnson, Liane B. , Cotton, Robin T., Willging, J. Paul, Zdanski, Carlton J. , Manoukian, John J. , Lam, Derek J. , Gantwerker, Eric A. , Husein, Murad , Inglis, Andrew F., Green, Glenn E. , Javia, Luv, Schraff, Scott A. , Soma, Marlene , Deutsch, Ellen S. , Sobol, Steven E., Ida, Jonathan B., Choi, Sukgi S. , Uwiera, Trina C., Shah, Udayan K. , White, David R. , Wootten, Christopher T. , El‐Hakim, Hamdy , Bromwich, Matthew, Richter, Gresham T. , Vijayasekaran, Shyan , Smith, Marshall E. , Vaccani, Jean‐Philippe , Hartnick, Christopher J. , Faucett, Erynne A. , Sidell, Douglas R. , Hong, Paul , Prager, Jeremy D , Nguyen, Lily H P , Zur, Karen , Sidell, Douglas R , Hart, Catherine K , Gantwerker, Eric A , Husein, Murad , Choi, Sukgi , Hartnick, Christopher J , Faucett, Erynne A , Johnson, Romaine F , Sidell, Douglas R , Ishman, Stacey L , Lam, Derek J , Balakrishnan, Karthik , Chun, Robert H. , Hart, Catherine K. , Bauman, Nancy M.

Mayo Clinic

The Laryngoscope | December 10, 2019 | Volume: 130 | Issue: 11 | Pages: 2700-2707

10.1002/lary.28461 | PMID 31821571 Get It

Objectives/HypothesisCreate a competency‐based assessment tool for pediatric tracheotomy.Study DesignBlinded, modified, Delphi consensus process.MethodsUsing the REDCap database, a list of 31 potential items was circulated to 65 expert surgeons who perform pediatric tracheotomy. In the first round, items were rated as “keep” or “remove,” and comments were incorporated. In the second round, experts were asked to rate the importance of each item on a seven‐point Likert scale. Consensus criteria were determined a priori with a goal of 7 to 25 final items.ResultsThe first round achieved a response rate of 39/65 (60.0%), and returned questionnaires were 99.5% complete. All items were rated as “keep,” and 137 comments were incorporated. In the second round, 30 task‐specific and seven previously validated global rating items were distributed, and the response rate was 44/65 (67.7%), with returned questionnaires being 99.3% complete. Of the Task‐Specific Items, 13 reached consensus, 10 were near consensus, and 7 did not achieve consensus. For the 7 previously validated global rating items, 5 reached consensus and two were near consensus.ConclusionsIt is feasible to reach consensus on the important steps involved in pediatric tracheotomy using a modified Delphi consensus process. These items can now be considered to create a competency‐based assessment tool for pediatric tracheotomy. Such a tool will hopefully allow trainees to focus on the important aspects of this procedure and help teaching programs standardize how they evaluate trainees during this procedure.Level of Evidence5 Laryngoscope, 130:2700–2707, 2020